Angiotensin blockade with eprosartan: vascular and functional implications

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• The renin-angiotensin system (RAS) and sympathetic nervous system (SNS) are crucial in maintaining elevated blood pressure, increasing risks for cardiovascular, cerebrovascular, and kidney diseases.
• Angiotensin II type 1 receptor blockers (ARBs) are antihypertensive agents that inhibit AT1 receptors, but eprosartan uniquely inhibits both pre- and postsynaptic AT1 receptors.

Purpose of the Study:

• To review the multifaceted effects of eprosartan, an ARB, on blood pressure and beyond.
• To highlight eprosartan's dual modulation of RAS and SNS and its impact on cardiovascular, cerebrovascular, and renal health.

Main Methods:

• Review of clinical studies and scientific literature on eprosartan's pharmacological actions.
• Analysis of eprosartan's effects on blood pressure, vascular inflammation, oxidation, lipoprotein modification, platelet aggregation, kidney function, and left ventricular dysfunction.

Main Results:

• Eprosartan significantly reduces systolic blood pressure (SBP), particularly in isolated systolic hypertension, by modulating both RAS and SNS.
• Eprosartan demonstrates benefits beyond blood pressure reduction, including anti-inflammatory and antioxidant effects, improved lipoprotein profiles, and positive impacts on kidney and cardiac function.
• Eprosartan's inhibition of prejunctional AT1 receptors influences noradrenaline release, contributing to its overall efficacy.

Conclusions:

• Eprosartan is an effective antihypertensive agent that modulates both the RAS and SNS.
• The benefits of eprosartan extend beyond blood pressure control, offering protection against major cardiovascular, cerebrovascular, and renal complications.
• Clinical evidence supports eprosartan's role in managing hypertension and preventing associated end-organ damage.